Hemostasis Today

May, 2026
May 2026
M T W T F S S
 123
45678910
11121314151617
18192021222324
25262728293031
Laura Dormer: Real-World Safety of DOACs vs LMWH in Cancer-Associated VTE Acroos Europe
May 28, 2026, 16:11

Laura Dormer: Real-World Safety of DOACs vs LMWH in Cancer-Associated VTE Acroos Europe

Laura Dormer, Co-Founder and Editorial Director at Becaris Publishing, shared on LinkedIn about a recent article by Ellen Brodin et al, published in Journal of Comparative Effectiveness Research, adding:

”Comparative safety of direct oral anticoagulants and low-molecular-weight heparin in patients with venous thromboembolism and cancer in Europe

Using observational healthcare datasets from five European countries, in this real-world study the authors examined bleeding outcomes associated with apixaban, rivaroxaban and low-molecular-weight heparin in routine clinical practice.

The study adds important real-world evidence to support treatment decision-making in oncology and thrombosis care.”

Title: Comparative safety of direct oral anticoagulants and low-molecular-weight heparin in patients with venous thromboembolism and cancer in Europe

Authors: Ellen Brodin, Annie Young, Florian Langer, Raza Alikhan, Lauri Timo, Dimitra Lambrelli, Beth Nordstrom, Alison Booth, Sophie Graham, Ruth Mokgokong, Aaron Jenkins, Jose Chaves, Feng Dai, Rupesh Subash, Moritz Lehne, Marco Ghiani, Antje Mevius, Daniela Fliegner, Anders Gottsäter

Laura Dormer: Real-World Safety of DOACs vs LMWH in Cancer-Associated VTE Acroos Europe

Stay updated on all scientific advances with Hemostasis Today.